Zentalis Pharma

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

cancer

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

ZNTL

The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals&#39; azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.

FDA Removes Partial Hold On Zentalis Pharmaceuticals&#39; Azenosertib Studies In Patients With Gynecological Cancers

Intraday Update

Markets

ALAR

AMIX

ASNS

AWIN

AZTR

CABA

CHGG

CHWY

CMTL

CVAC

DMTK

ELWS

GERN

KARO

KAVL

Kintara Therapeutics, Inc. - Common Stock

KTRA

MBIO

MESA

MYND

NGNE

NLSP

NVAX

PDCO

PSNY

QMCO

RELI

RKLB

SCNI

SILK

SKYE

SNOA

SVMH

SYNX

TOST

TRNR

TSHA

VRPX

Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Zentalis Pharmaceuticals announced the FDA&#39;s partial clinical hold on azenosertib studies due to recent patient deaths.

Why Is Small-Cap Cancer-Focused Zentalis Pharma Stock Trading Lower On Tuesday?

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharmaceuticals Inc

Press Releases

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL

Penny Stocks

Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVTE

CTRX

DVAX

HPTX

HZNP

MRNA

TARS

ZSPH

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Alector

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Coya Therapeutics

Editas Medicine

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Inventiva S.A. - American Depository Shares

Inventiva

Seres Therapeutics

Macrogenics

Nuvectis Pharma

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Renovaro

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sutro Biopharma

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Instil Bio

2seventy bio

Vor Biopharma

Wells Fargo

HC Wainwright & Co.

Guggenheim

Oppenheimer

Comments

Zentalis Pharma

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga